Esther N. Oliva

Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Anemia and Patient-Reported Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Real-World Observational Study.

Anemia and Patient-Reported Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Real-World Observational Study.

Journal: EJHaem

Published: July 13, 2026

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

Journal: Future oncology (London, England)

Published: July 11, 2026

Review, conceptual model, and gap analysis of transfusion burden in hematological diseases.

Review, conceptual model, and gap analysis of transfusion burden in hematological diseases.

Journal: Expert review of hematology

Published: May 14, 2026

Relationships Between Clinician-Patient Communication and the Quality of Life of Patients With Leukaemia: A Prospective Cross-Sectional Global Study.

Relationships Between Clinician-Patient Communication and the Quality of Life of Patients With Leukaemia: A Prospective Cross-Sectional Global Study.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: March 31, 2026

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

Journal: American journal of hematology

Published: January 30, 2026

Sustained Erythroid Response to Eltrombopag in Low-Risk Myelodysplastic Neoplasms With Severe Anemia and Thrombocytopenia: A Case Report.

Sustained Erythroid Response to Eltrombopag in Low-Risk Myelodysplastic Neoplasms With Severe Anemia and Thrombocytopenia: A Case Report.

Journal: Case reports in hematology

Published: January 10, 2026

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy.

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy.

Journal: Therapeutic advances in hematology

Published: December 24, 2025

Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review.

Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review.

Journal: Journal of patient-reported outcomes

Published: November 01, 2025

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.

Journal: Blood neoplasia

Published: October 15, 2025

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Journal: Haematologica

Published: August 21, 2025

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.

Journal: British journal of haematology

Published: July 29, 2025

Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.

Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.

Journal: The Lancet. Haematology

Published: July 22, 2025

Showing 1-12 of 89

Last Updated: 09/26/2026